Skip to main content
SpringerLink
Log in

The usefulness of18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor

  • Original Articles
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Liver tumors, especially hepatocellular carcinomas (HCCs), often exhibit no contrast with surrounding non-tumorous liver tissue in F-18-fluoro-2-deoxy-2-fluoro-d-glucose (FDG) positron emission tomography (PET) images obtained at the usual interval of one hour after intravenous FDG injection. We evaluated the usefulness of FDG PET studies of liver tumors performed 2 hours after intravenous injection.Methods and Materials: Fifteen pretherapeutic patients with 33 liver tumors were studied, including 11 patients with 18 HCCs, and 4 patients with 15 metastatic liver tumors (METAs) from 3 colorectal carcinomas and 1 esophageal carcinoma. After transmission scans, emission scans were obtained 45–55 minutes and 115–125 minutes after intravenous injection of 185–370 MBq FDG as early images and delayed FDG PET images, respectively. Visual analysis of early and delayed images was performed, and the FDG uptake in the tumor to that in nontumorous liver ratio (T/N ratio), the FDG uptake in tumor to that in soft-tissue ratio (T/S ratio) and the FDG uptake in non-tumorous liver to that in soft-tissue ratio (N/S ratio) were calculated for each image.Results: In visual analysis, visual improvement seen in images was observed in 6 of 18 HCC lesions and all 15 META lesions. In quantitative analysis, the mean T/S ratio and T/N ratio of HCCs in early images were 4.97 and 1.90, respectively, and those in delayed images were 6.24 and 2.20, respectively. The mean T/S ratio and T/N ratio of METAs in early images were 5.97 and 2.21, respectively, and those in delayed images were 6.99 and 3.80, respectively. The T/S ratio of HCCs and T/S ratio and T/N ratio of METAs were significantly higher in delayed images than in early images. The mean N/S ratios of HCC cases were 2.58 in the early images and 2.57 in the delayed images, but the ratio showed no constant tendency in the images. All N/S ratios of META cases were decreased in delayed images, although the significance of the small number of cases.Conclusion: FDG PET studies performed 2 hours after intravenous injection were useful for clear visualization of liver tumors, especially metastatic liver tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32: 623–648; discussion 649–650.

    PubMed  CAS  Google Scholar 

  2. Choi JY, Kim SE, Shin HJ, Kim BT, Kim JH. Brain tumor imaging with99mTc-tetrofosmin: comparison with201Tl,99mTc-MIBI, and18F-fluorodeoxyglucose.J Neurooncol 2000; 46: 63–70.

    Article  PubMed  CAS  Google Scholar 

  3. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucosepositron emission tomography in the detection and staging of lung cancer.Am J Respir Crit Care Med 1996; 153: 417–421.

    PubMed  CAS  Google Scholar 

  4. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, et al. Diagnosis of pancreatic carcinoma: role of FDG PET.Am J Roentgenol 1998; 171: 1565–1570.

    CAS  Google Scholar 

  5. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer.J Nucl Med 1999; 40: 1125–1131.

    PubMed  CAS  Google Scholar 

  6. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment [see comments].J Nucl Med 1992; 33: 333–339.

    PubMed  CAS  Google Scholar 

  7. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al.In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.J Nucl Med 1995; 36: 1811–1817.

    PubMed  CAS  Google Scholar 

  8. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography [see comments].Ann Surg Oncol 1997; 4: 613–620.

    Article  PubMed  CAS  Google Scholar 

  9. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Pege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET.J Comput Assist Tomogr 1992; 16: 684–689.

    Article  PubMed  CAS  Google Scholar 

  10. Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.Arch Surg 1996; 131: 703–707.

    PubMed  CAS  Google Scholar 

  11. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool.Invest Radiol 1987; 22: 360–371.

    Article  PubMed  Google Scholar 

  12. Bida GT, Satyamurthy N, Barrio JR. The synthesis of 2-[F-18]fluoro-2-deoxy-d-glucose using glycals: a reexamination.J Nucl Med 1984; 25: 1327–1334.

    PubMed  CAS  Google Scholar 

  13. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography.Arch Surg 1998; 133: 510–515; discussion 515–516.

    Article  PubMed  CAS  Google Scholar 

  14. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.J Nucl Med 1994; 35: 1965–1969.

    PubMed  CAS  Google Scholar 

  15. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments].J Clin Oncol 1996; 14: 700–708.

    PubMed  CAS  Google Scholar 

  16. Enomoto K, Okazumi S, Fukunaga T, Asano T, Kikuchi T, Nagashima T, et al. The efficacy of18F-fluorodeoxyglucose positron emission tomography for the evaluation of hepato-cellular carcinoma treatment (in Japanese).Kanzo 1993; 34: 464–470.

    Google Scholar 

  17. Okazumi S, Enomoto K, Ozaki M, Yamamoto H, Yoshida M, Abe Y, et al. Evaluation of the effect of treatment for patients with liver tumors using18F-fluorodeoxyglucose PET (in Japanese).KAKU IGAKU (Jpn J Nucl Med) 1989; 26: 793–797.

    CAS  Google Scholar 

  18. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation and growth rates of transplanted rat tumors.Cancer Res 1970; 30: 2240–2244.

    PubMed  CAS  Google Scholar 

  19. Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.Br J Surg 1999; 86: 194–199.

    Article  PubMed  CAS  Google Scholar 

  20. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection.Eur J Nucl Med 2001; 28: 696–703.

    Article  PubMed  CAS  Google Scholar 

  21. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose.J Nucl Med 19: 1154–1161, 1978.

    PubMed  CAS  Google Scholar 

  22. Fukuda H. Diagnosis of liver tumors with18F-FDG and18F-FDGal using PET (in Japanese).Nippon Rinsho 1991; 49: 1863–1867.

    PubMed  CAS  Google Scholar 

  23. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with18F-FDG to detect residual disease after therapy for malignant lymphoma.Nucl Med Commun 1998; 19: 1055–1063.

    Article  PubMed  CAS  Google Scholar 

  24. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.Eur J Nucl Med 1997; 24: 678–682.

    PubMed  CAS  Google Scholar 

  25. Peterson MS, Baron RL. Radiologic diagnosis of hepato-cellular carcinoma.Clin Liver Dis 2001; 5: 123–144.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Osaka City University School of Medicine, 1-5-7, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan

    Joji Kawabe & Hironobu Ochi

  2. Department of Radiology, Osaka City University, 1-5-7, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan

    Koichi Koyama, Terue Okamura, Nozomi Ozawa, Shigeaki Higashiyama & Ryusaku Yamada

Authors
  1. Koichi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terue Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joji Kawabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nozomi Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeaki Higashiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hironobu Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryusaku Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koichi Koyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koyama, K., Okamura, T., Kawabe, J. et al. The usefulness of18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16, 169–176 (2002). https://doi.org/10.1007/BF02996297

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02996297

Key words

Search

Navigation